New combo therapy aims to turn inoperable liver cancer into a curable condition
NCT ID NCT06187961
First seen Apr 25, 2026 · Last updated May 25, 2026 · Updated 4 times
Summary
This study tests a combination of chemotherapy infused directly into the liver artery plus two oral drugs (lenvatinib and cadonilimab) in 42 adults with liver cancer that cannot be removed surgically. The goal is to shrink tumors enough so that patients can then receive curative treatments like surgery, ablation, or a liver transplant. The study is currently active but no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Conditions
Explore the condition pages connected to this study.